Aldeyra Therapeutics Achieves Goals In Crossover Clinical Trial Of 0.25% Reproxalap Solution
(RTTNews) - Aldeyra Therapeutics, Inc. (ALDX) announced Tuesday the achievement of the primary endpoints in a sequence-randomized, double-masked, vehicle-controlled crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease.
Reproxalap was statistically superior to vehicle for each of the two prespecified primary endpoints, ocular redness in a dry eye chamber and Schirmer test, a measure of tear production, after a single day of dosing.
The secondary endpoint of Schirmer test =10 mm responder analysis, which was multiplicity-controlled, was also achieved.
A pre-NDA meeting with the FDA has been scheduled for the third quarter of 2022.
For More Such Health News, visit rttnews.com
Aldeyra Therapeutics Gets CRL From FDA For NDA Of ADX-2191 To Treat Primary Vitreoretinal Lymphoma
TSX Falls 1% As Materials Shares Tumble
Dollar Rises Sharply Against Major Counterparts After Upbeat Jobs Data
U.S. Consumer Credit Climbs Much Less Than Expected In April
Why Do Economists Think Jobs Report Could Delay Fed Rate Cuts?
Swiss Market Ends Marginally Up
European Stocks Close Lower As Investors Move Past ECB Rate Cut, Digest U.S. Jobs Data
